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Abstract: Benign prostatic hyperplasia (BPH) is a complex and progressive disease common in 
aging men. While associated with bothersome lower urinary tract symptoms, it may also result 
in additional serious complications such as refractory hematuria, acute urinary retention, and 
BPH-related surgery. Medical therapy has been offered as an approach to halt this progression 
and perhaps reverse the pathophysiology of BPH. While alpha-blockers provide rapid relief 
in the form of improved flow rate, their effects may not reduce the overall risk of BPH-related 
complications. 5α-reductase inhibitors were therefore introduced to affect the underlying disease 
process by inhibiting the enzyme which converts testosterone to dihydrotesterone, the primary 
androgen involved in normal and abnormal prostate growth. Through this inhibition, prostate 
size is decreased, thereby reducing the risk of acute urinary retention and BPH-related surgery 
while providing symptom control. These effects are most pronounced in men with enlarged 
prostates (25 mL) who are at the greatest risk of disease progression. This article reviews the 
literature for finasteride used in the treatment of BPH and provides evidence for its efficacy, 
safety and tolerability, applicability for combination therapy, and considerations of its effects 
on prostate cancer risk.
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Introduction
Benign prostatic hyperplasia (BPH) is a pathologic process which may contribute 
to lower urinary tract symptoms in aging men. A common problem among males 
over 50 years, its prevalence increases with age and many longitudinal studies 
have demonstrated the progressive nature of the disease.1 Histologically, BPH 
is characterized by an increased number of both epithelial and stromal cells in the 
periurethral area of the prostate. There is controversy as to whether this increase is 
secondary to epithelial and stromal proliferation or impaired apoptosis leading to 
cellular accumulation. Nevertheless, it is understood that androgens, growth factors, 
neurotransmitters and other cell interactions play a role in the development of this 
condition.
While alpha-blockers provide rapid relief in the form of improved flow rate, their 
effects may not reduce the overall risk of BPH-related complications. 5α-reductase 
inhibitors were therefore introduced to impact underlying disease by inhibiting the 
enzyme which converts testosterone to dihydrotesterone (DHT), the primary androgen 
involved in normal and abnormal prostate growth. Through this inhibition, prostate 
size is decreased, thereby reducing the risk of acute urinary retention and BPH-related 
surgery while providing symptom control. As a drug which blocks the type 2 isoenzyme Therapeutics and Clinical Risk Management 2009:5 536
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of 5α-reductase, finasteride’s effects on the prostate and 
symptoms attributable to benign prostatic hyperplasia have 
been well documented in the literature. These effects are most 
pronounced in men with enlarged prostates (25 mL) who 
are at the greatest risk of disease progression. This article 
reviews the literature for finasteride used in the treatment 
of BPH and examines the mode of action of finasteride, its 
efficacy, safety and tolerability profiles and its role in com-
bination therapy and prostate cancer risk.
Mode of action
Normal and abnormal growth of the prostate is dependent 
on the presence of hormones and growth factors. The most 
important of these is testosterone which is converted within 
the prostate into its more active metabolite, dihydrotestos-
terone (DHT), by 5α-reductase, a nuclear-bound steroid 
enzyme localized primarily in the prostatic stromal cell. 
This cell plays an important role in androgen-dependent 
prostatic growth.
Two isoenzymes have been identified, each encoded by 
a separate gene.2,3 The predominant enzyme in extrapros-
tatic tissue such as the skin or liver is type 1 5α-reductase. 
Conversely, the predominant prostatic enzyme is type 2 
5α-reductase. This latter enzyme is critical to normal devel-
opment of the prostate and hyperplastic growth later in life. 
type 2 5α-reductase is extremely sensitive to inhibition 
by both finasteride as well as dutasteride, a dual type 1, 
type 2 5α-reductase inhibitor.4 Given that several studies 
have demonstrated identical prostate size reduction between 
patients treated with finasteride as well as dual type 1, type 2 
inhibitors (such as dutasteride), the role of type 1-derived 
DHT is unlikely to be clinically meaningful.
As a competitive inhibitor of type 2 5α-reductase, finaste-
ride prevents the conversion of testosterone to DHT, thereby 
lowering both serum and intraprostatic DHT levels. A study 
by Norman and colleagues revealed that finasteride reduced 
intraprostatic DHT level by 91.4%.5 However, finasteride 
does not reduce DHT levels to castrate levels since circulating 
testosterone is converted to DHT by the type 1 isoenzyme 
existing in the skin and liver.
Although the pathophysiology of clinical BPH is not 
considered to be dependent on prostate size, reducing 
the prostate’s volume is thought to decrease the constant 
component of bladder outlet obstruction. Furthermore, men 
with a prostate volume of 30 cm3 or more have been shown 
to be 3.5 times more likely to have moderate-to-severe 
lower urinary tract symptoms and acute urinary retention.6 
Therefore, by actively decreasing the size of the prostate 
through reduction of intraprostatic DHT,7 finasteride 
arguably plays an important role in the reduction of long-
term risk of progression.
Efficacy
Prostate volume, BPH symptoms 
and BPH progression
The effects of finasteride on prostate size have been studied 
extensively with maximal reduction of prostate volume 
achieved within 6 months.8 Since the mechanisms underlying 
finasteride’s positive effects on prostate outcomes are thought 
to be mediated by volume reduction, one can assume that 
subjects with larger prostates may achieve greater benefit. 
Therefore, the majority of randomized, placebo-controlled 
trials have evaluated subjects with larger prostates which 
creates difficulty in generalizing to a typical patient, with 
normal-sized prostate.9
The first multicenter, randomized, double-blind, placebo-
controlled clinical trial investigating the efficacy of finasteride 
was performed by Gormley and colleagues in 1992 and is 
often referred to as the North American Finasteride Trial.8 As 
mentioned above, the baseline prostate volumes in both the 
placebo and experimental groups (measured by transrectal 
ultrasound) were quite large (60 cm3), limiting its application 
to men with more typical size prostates. Eight hundred and 
ninety-five subjects with BPH were randomized to receive 
placebo or 1 or 5 mg of finasteride for 1 year. The primary 
outcome measures consisted of a modified Boyarsky symp-
tom score and peak flow rate, although measurements of 
prostate volume were also recorded as a secondary outcome. 
The modified Boyarsky symptom score, originally described 
by Boyarsky and colleagues12 and modified and validated by 
Bolognese et al13 was computed as the total sum of scores of 
nine symptoms: decreased urinary stream, dribbling, inter-
ruption in stream, hesitancy, feeling of incomplete emptying, 
straining to initiate flow, urgency, incontinence, and dysuria. 
Results demonstrated a mean percentage change in symptom 
score at 12 months of −2%, 9%, and 21% in the placebo, 1-mg, 
and 5-mg finasteride groups, respectively. These results were 
statistically significant when comparing placebo and 5-mg 
finasteride groups but not for the 1-mg group. Mean percentage 
changes in peak flow rate were 8%, 23%, and 22% while the 
mean percentage changes in prostate volume were −3%, −18%, 
and –19% respectively. A secondary analysis attempted to cor-
relate symptom score improvement with reduction of prostate 
size. However, this did not prove to be dose-dependent, sug-
gesting that the efficacy of finasteride may not be exclusively 
mediated by the reduction of prostate volume.Therapeutics and Clinical Risk Management 2009:5 537
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Following this initial study, a second report was published 
in 1993, termed the International Finasteride Study.10 Known 
as the Finasteride Study Group, these researchers reported 
another multicenter, randomized, double-blind, placebo-
controlled clinical trial which described the effect of finaste-
ride on symptom score, peak flow rate, and prostate volume. 
Measured via transrectal ultrasound, the mean prostate 
volume here was also relatively large (47 cm3), including 
only prostates above 30 cm3. Results were in agreement 
with the North American Finasteride Trial, demonstrating 
a prostate volume reduction of 22% (P  0.001), increased 
peak flow rate by 1.7 mL/sec (P  0.025) and improved 
symptom score by 3.3 points (P = 0.005).
While the above studies were favorable with regard to 
peak flow rate, prostate size reduction, and symptom score, 
they also demonstrated bias toward larger prostates, which 
presents difficulty in generalizing to a more typical patient 
population. The first study to examine the efficacy of finaste-
ride on smaller prostate size was performed by Andersen and 
colleagues in 1995.11 Unlike prior studies, the mean prostate 
size in this study was approximately 40 mL. Seven hundred 
and seven patients were maintained on either placebo or 
finasteride for 2 years. Primary outcome measures included a 
modified Boyarsky symptom score, peak flow rate and prostate 
volume, and these were examined at both 12 and 24 months. 
The group mean difference from placebo was statistically 
significant but the mean change was less than that shown in 
the both the North American Finasteride Trial as well as the 
International Finasteride Study. Time-dependent symptom 
score changes demonstrated a placebo response which returned 
to baseline by year 2 whereas the finasteride response remained 
effective throughout the study time period. Mean differences 
between symptom scores of the placebo and finasteride groups, 
however, were not markedly different, with –0.3 and 0.6 units 
change in symptoms between 12 and 24 months, respectively. 
However, when assessing mean change of symptom score 
between baseline and month 24, a more dramatic change 
of symptom score is demonstrated in the finasteride group 
(2 units) compared to placebo (0.2 units) (P  0.01). Although 
statistically significant, one may question the clinical applica-
tion of a small difference between the two groups.
In 1994, Stoner and colleagues took advantage of the 
previously described large sample sizes of both the North 
American Finasteride Trial and International Finasteride Study, 
offering these subjects an open-label extension after completing 
1 year of randomized therapy.14 As a long-term, 3-year efficacy 
analysis, 543 subjects were included in the study, although only 
55% of patients continued to participate through the trial’s 
3-year duration (297 subjects). Two important findings emerged 
from this study. First, the largest change in symptom score, 
prostate volume, and peak flow rate occurred between 12 and 
18 months, coinciding with the transfer of blinded to unblinded 
treatment. Second, after 18 months of therapy, the previously 
described changes remained stable, suggesting durability of 
response. Hudson and associates took this one step further, 
extending the analysis to five years and confirming durability 
of response for this time period as well.15
Another long-term study, the Proscar Long-Term Efficacy 
and Safety Study (PLESS), represents the double-blind, 
randomized, placebo-controlled study with the longest 
follow-up assessment to date in the medical therapy of BPH.7 
During this 4-year study, 3040 men with moderate-to-severe 
urinary symptoms were randomized to either 5 mg of daily 
finasteride or placebo. Mean prostate size was 55 cm3 in this 
study (measured via transrectal ultrasound, similar to prior 
studies), suggesting a bias toward subjects with larger prostates. 
Symptom scores, urinary flow rate, and outcome events 
were assessed every four months. A quasi-AUA (American 
Urological Association) symptom score was used with a 
mean change between placebo and treatment of 2.0 symptom 
units. Mean increased peak flow rate and size reduction were 
1.7 mL/sec and 32% respectively for those in the active 
finasteride group. Similar to Andersen’s study, this confirmed 
durability of response as well as modest efficacy. Subjects 
within the finasteride group also demonstrated increased flow 
rates (P  0.001), reduced prostate volume (P  0.001) and 
a larger mean decrease in symptom score (P  0.001) when 
compared to placebo. Of note, the symptom score was a 
self-administered questionnaire different from the now-accepted 
American Urological Association symptom score (as this was 
not yet created). However, the authors did attempt to adjust the 
symptom score sum to fit the AUA symptom scale, noting that 
they utilized a “quasi-AUA score.”
Compared to prior randomized controlled trials, PLESS 
additionally evaluated the incidence of other outcome mea-
sures including acute urinary retention and surgical interven-
tion for BPH. Results demonstrated a risk reduction of 55% 
in men in the finasteride group with surgical intervention 
required in 10% of those in the placebo group and 5% in the 
finasteride group (P  0.001). Acute urinary retention was 
also decreased in the finasteride group by 57% with 7% of 
the placebo and only 3% of the finasteride group developing 
this complication (P  0.001).
One important consideration for this study involves 
the inclusion criteria, which enrolled men with moderate-
to-severe symptoms as well as an enlarged prostate on digital Therapeutics and Clinical Risk Management 2009:5 538
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rectal examination. In fact, mean prostate size was measured 
to be approximately 55 cm3. Therefore, caution is warranted 
when attempting to generalize the results of this study to men 
without prostatic enlargement.
As there have been a number of randomized, placebo-
controlled clinical trials, Boyle and associated undertook a 
meta-analysis of six randomized, placebo-controlled clinical 
trials to provide a more thorough consensus.16 The most mean-
ingful finding was the demonstration of a positive correlation 
between mean change in symptom score and peak flow rate 
with mean baseline prostate volume, indicating that studies 
incorporating patients with larger prostates demonstrated 
greater improvements, which may account for the variability 
of treatment effect described in the above studies. For the 
2601 men included in the analysis, there was a mean symp-
tom improvement of 1.8 points in prostate volumes 20 cm3 
compared to 2.8 points in larger prostates (60 cm3) on the 
Quasi-AUA Scale. Improvements in peak flow rate were also 
demonstrated. While men with prostate volumes 20 cm3 
demonstrated improvement of 0.89 mL/sec, this was increased 
significantly to 1.84 mL/sec in men with volumes 60 cm3. 
As described by Boyle, approximately 80% of the variation in 
treatment effect between studies was attributed to differences 
in mean prostate size.
Offering a different perspective on finasteride efficacy, 
Tammela and colleagues reported on a randomized, double-
blind, placebo-controlled study which examined the effects of 
finasteride on men with bladder outlet obstruction who were 
on a waiting list for prostatectomy.17 Urodynamic evaluation 
was conducted in 36 men in whom mean prostate volumes 
in finasteride and placebo groups were 50 and 48 cm3, 
respectively. Mean baseline detrusor pressures at maximal flow 
were 126 and 115 cm H2O in the finasteride and placebo groups, 
respectively. After 6 months of treatment, mean changes in 
the detrusor pressure at maximal flow were −39 and +3 cm 
H2O in the finasteride and placebo groups, respectively. 
While the results were statistically significant (P  0.01), the 
patients in the finasteride group still required surgery to relieve 
obstruction, and the symptom score changes were not different 
between the two groups. This study was extended for 4 years 
as an open-label extension and this revealed further improve-
ment of detrusor pressure at maximal flow over time with only 
five patients requiring surgery, demonstrating that an operation 
could be avoided with long-term finasteride therapy.18
Hematuria
In addition to the obvious benefits of prostate volume reduc-
tion and the halt of BPH progression, finasteride has also 
been positively associated with a reduction of refractory gross 
hematuria secondary to BPH. Initial reports were described 
by Puchner and Miller in 1995 in which a case series of 
12 patients were studied.19 A hematuria grading system was 
devised, demonstrating 92% improvement in the hematuria 
grade after more than 3 months of therapy with finasteride. 
This was reconfirmed in 1998 with a follow-up case series, 
in which results were extended to a mean follow-up of 
3 years, demonstrating decrease in hematuria grade over 
this time period during finasteride therapy.20 A second 
case series provided by Carlin and colleagues in 199721 led 
to the development of a randomized, placebo-controlled, 
double-blind clinical trial by Foley and coworkers in 2000.22 
Fifty-seven patients with chronic intermittent hematuria 
were randomized to either finasteride or placebo. Hematuria 
was found to recur in 17 (63%) of the untreated control 
group but only 4 (14%) in the finasteride group (P  0.05). 
Surgery was required in 7 (26%) of patients in the control 
group while no finasteride-treated patient required surgery 
for refractory hematuria. Based on these studies, finasteride 
is now recommended in patients with hematuria secondary 
to benign prostatic hyperplasia.
The exact mechanism of finasteride’s beneficial effect 
on BPH-related hematuria is unknown, although multiple 
studies have investigated this question. Donohue and asso-
ciates published their experience with 64 men scheduled 
to undergo TURP who were randomized to receive either 
5 mg of finasteride or placebo daily for 2 weeks prior to 
surgery.23 Sections of prostatic urothelium were stained for 
VEGF expression and for CD31 to assess microvessel density 
(MVD) (an indicator of prostatic angiogenesis in patients 
with hematuria secondary to BPH). Mean MVD was found 
to be significantly lower in the finasteride group compared 
to placebo (P  0.01) leading to the conclusion that finaste-
ride inhibits angiogenic growth factors which contribute to 
reduced vascularity and decreased BPH-related hematuria, 
even as early as 2 weeks. Memis and colleagues confirmed 
these findings by evaluating short-term finasteride treatment 
on MVD.24 Similar to the findings by Donohue, mean MVD 
was found to be significantly lower in patients treated with 
finasteride compared to control patients (P  0.05).
These findings were extended by evaluating finasteride’s 
usefulness in BPH TURP candidates. Ozdal and colleagues 
evaluated the effect of short-term finasteride therapy on peri-
operative bleeding in candidates for transurethral resection 
of the prostate.25 Forty patients with BPH were randomized 
into two groups with the first group receiving 5 mg finaste-
ride for 4 weeks prior to surgery and the other established as Therapeutics and Clinical Risk Management 2009:5 539
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the control. Patients who had received finasteride or any other 
anticoagulant in the past were excluded from the study. No 
significant difference in baseline age, IPSS, prostate volume, 
or preoperative hemoglobin or hematocrit was demonstrated. 
The total blood loss and bleeding per gram of resected tissue 
were significantly lower in the finasteride group regardless 
of prostate volume (P  0.05 and P  0.0001, respectively). 
Furthermore, a smaller decrease in hemoglobin and hemato-
crit was found in the finasteride group (P  0.0001). Given 
these findings, finasteride is recommended not only for 
patients with BPH-related hematuria but TURP candidates 
as well for 2 to 4 weeks prior to scheduled surgery.
Tolerability and adverse effects
Although the efficacy of finasteride in reducing prostate volume 
and improving peak flow rate and symptom score has been 
established, particularly for prostate volumes 30 cm3, this 
must be weighed against the potential for adverse effects associ-
ated with treatment. However, several trials have demonstrated 
that finasteride is well tolerated with minimal side effects.
The majority of trials note that the most common side 
effect is sexual dysfunction and does not constitute a clini-
cally meaningful cause of treatment withdrawal.7,8,11 For 
instance, the North American Finasteride Trial evaluated 
the withdrawal rate of patients secondary to adverse events.8 
The most common side effects included decreased libido, 
ejaculatory disorder, and erectile dysfunction, with rates of 
3.4%, 2.7%, and 1.7% in the 5 mg finasteride group. Despite 
these adverse effects, the percentage of subjects withdrawing 
secondary to adverse effects did not differ in the placebo and 
treatment groups. Similarly, the International Finasteride 
Trial confirmed the most common adverse effect was erectile 
dysfunction (reported in 4.9% in the 5 mg group compared 
to 0.4% in the placebo group) (P = 0.001). No differences 
were noted in baseline or follow-up endocrine status identi-
fied in men with or without erectile dysfunction. Despite this 
side effect, only 1 patient out of 246 (0.4%) discontinued the 
study because of this side effect. No other adverse clinical 
effects were noted in the study.
Although the most common side effect for finasteride 
is sexual dysfunction, the clinical relevance of this finding 
has recently been called into question. A recent randomized, 
placebo-controlled study conducted by Mondaini and 
colleagues suggests a “nocebo” effect (an adverse side 
effect that is not a direct result of the pharmacologic action 
of the drug).26
One hundred and twenty patients were randomized to 
receive finasteride 5 mg (concealed identity) either with 
or without counseling on the drug’s sexual side effects. 
Estimation of side effects was determined at 6 and 12 months 
using the male sexual function-4 (MSF-4) item questionnaire 
as well as a self-administered questionnaire. Interestingly, 
those patients with prior counseling reported a significantly 
higher proportion of sexual side effects with the incidence 
of ED, decreased libido, and ejaculation disorders of 30.9%, 
23.6% and 16.3%, respectively compared to 9.6%, 7.7% and 
5.7% in the noncounseled group.
The minimal effect of finasteride on sexual function was 
further confirmed by the Prostate Cancer Prevention Trial, a 
randomized, double-blind, placebo-controlled clinical trial 
which is described in further detail later in this review.27 
Sexual dysfunction was studied in over 17,000 patients 
during a 7-year period. A multitude of questionnaires were 
utilized to assess sexual dysfunction, including Sexual 
Activity Scale score, SF-36 Mental Health Inventory-5, 
Physical Function, and Vitality scores and other comorbidi-
ties which may be attributable to sexual dysfunction. Mean 
sexual dysfunction increased in the finasteride arm from 
baseline by 2.11 Sexual Activity points at the end of study 
(P  0.001) on a total scale of 0–100. After adjusting for con-
founding variables, the absolute magnitude of this dysfunc-
tion decreased further. Although statistically significant, the 
clinical meaning of such a small change should be taken into 
account given that a large sample size may show statistical 
significance with small, clinically insignificant differences.
Other considerations have been made with regard to 
androgen suppression and its adverse effects. Because 
androgens can affect bone turnover, lipids, hematopoiesis, 
as well as sexual function, Amory and associates set out to 
determine whether 5α-reductase inhibitors negatively impact 
these end points.28 Conducting a randomized, double-blind, 
placebo-controlled trial, 99 men between 18 and 55 years old 
were randomized to receive either 0.5 mg dutasteride, 5 mg 
finasteride, or placebo for 12 months. Bone mineral density 
was measured at baseline, after 1 year and again at 6 months 
after drug discontinuation. Serum markers for bone turnover, 
fasting low-density lipoprotein, hemoglobin and prostate-
specific antigen (PSA) were measured at baseline, after 26 and 
52 weeks of treatment and at 24 weeks after drug discontinu-
ation. Results revealed no significant difference in placebo 
and 5α-reductase inhibitors for any of the above mentioned 
markers with the conclusion that suppression of serum DHT 
induced by finasteride during 12 months did not adversely 
affect bone turnover, serum lipoproteins, or hemoglobin.
In addition to physical side effects, animal studies have 
also described behavioral changes with the use of finasteride, Therapeutics and Clinical Risk Management 2009:5 540
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and case reports of finasteride-induced depression have also 
been reported in humans. This was formally evaluated by 
Rahimi-Ardabilli, in which 128 men with androgenic alopecia 
were prescribed 1 mg finasteride daily.29 Study subjects 
completed both the Beck Depression Inventory (BDI) and 
Hospital Anxiety and Depression Scale (HADS) before 
the start of treatment and after two months of use. Results 
demonstrated that finasteride-treated patients had significantly 
increased BDI and HADS depression scores (P  0.01). 
HADS anxiety scores were increased in the finasteride 
group, but this was statistically nonsignificant (P = 0.061). 
Although a randomized controlled trial specifically investi-
gating depression and anxiety will be necessary to confirm 
these findings, one should prescribe finasteride cautiously to 
patients with a high risk of depression.
Combination therapy
Efficacy
While many earlier studies assessed the efficacy of finasteride 
monotherapy, research into finasteride’s efficacy naturally 
progressed toward combination therapy and its role in the 
medical management of BPH. The initial multi-center, 
randomized, double-blind, placebo-controlled combination 
trial was published in 1996 by Lepor and associates and is 
known as the Veterans Affairs Cooperative Study No. 359.30 
One thousand two hundred and twenty-nine patients were 
randomized into one of four groups: placebo, terazosin, 
finasteride, and combination therapy (terazosin + finasteride). 
The dose of terazosin was titrated upward to 10 mg while 
5 mg of finasteride was provided to those patients in this 
treatment arm. Of the 1229 randomized patients, 1007 
(82%) completed 1 year of therapy. Mean prostate volume 
(measured with transrectal ultrasound) in each of the 
four groups ranged from 36 to 38 cm3 at baseline. The mean 
group differences between finasteride and placebo were not 
statistically significant for AUA Symptom Index, Symptom 
Problem Index, BPH Impact Index, and peak flow rate. In 
contrast, the mean differences between terazosin and finas-
teride were highly statistically significant, in favor of the 
former, unequivocally demonstrating that alpha blockade is 
superior to 5α-reductase inhibitors for treatment of clinical 
BPH over a 12-month period. The most likely explanation of 
the demonstrated decreased efficacy in this study compared to 
the prior studies with monotherapy is the decreased baseline 
prostate size included in the analysis. To address this concern, 
a sub-analysis was performed in patients with enlarged 
prostates (50 cm3).31 Not surprisingly, results from this 
sub-analysis revealed a statistically significant change in both 
peak flow rate as well as AUA symptom score by 2.0 mL/sec 
and 1 unit, respectively, compared to placebo.
The results of the VA Cooperative Study were confirmed 
by the Prospective European Doxazosin and Combination 
Therapy Trial (PREDICT) in which 1089 men were random-
ized equally to placebo, doxazosin, finasteride, and combina-
tion therapy.32 Daily dose of doxazosin was titrated up to 8 mg 
whereas 5 mg dosage was used for finasteride. Baseline pros-
tate volume was similar to that of the VA Cooperative Study at 
approximately 36 cm3. Improvement in peak flow rate, urinary 
retention and AUA Symptom Score were not significantly dif-
ferent between placebo and finasteride whereas improvements 
in these parameters were highly significantly different between 
doxazosin or combination therapy and placebo or finasteride, 
demonstrating little efficacy of finasteride in men with smaller 
prostate sizes over 12 months of therapy.
Another multicenter, randomized, double-blind, placebo-
controlled clinical trial investigated the efficacy of combina-
tion therapy with 5 mg SR alfuzosin and 5 mg finasteride over 
6 months of follow-up.33 Similar to the prior alpha-blocker 
combination trials, little improvement in IPSS was observed, 
and at 6 months peak flow rates were not significantly different 
in any of the treatment groups relative to controls.
While the above clinical trials did not show a beneficial 
effect of 5α-reductase inhibition, they were limited by rela-
tively short follow-up periods, with maximal follow-up of 
1 year in any given trial, thereby potentially favoring the 
fast-acting benefits of alpha blockers over 5α-reductase 
inhibitors. Therefore, the Medical Therapy of Prostatic 
Symptoms (MTOPS) Study was created to address the 
question of long-term benefit.34 Representing the longest 
and largest clinical trial conducted in patients with BPH, 
MTOPS evaluated whether finasteride combined with doxa-
zosin was more effective than either placebo or monotherapy 
in prevention of clinical progression of BPH over a period 
of 4.5 years. Constructed as a double-blind, randomized, 
placebo-controlled trial, 3047 men with BPH were enrolled 
with a wide variety of prostate sizes as long as the serum 
PSA was less than 10 ng/mL. Unlike prior studies, BPH 
progression was used as the primary endpoint, defined as an 
increase above baseline of at least 4 points in the American 
Urological Association symptom score, socially unacceptable 
urinary incontinence, a 50% increase in creatinine relative 
to baseline values, acute urinary retention, or two or more 
urinary tract infections within 1 year (or a single episode of 
urosepsis due to bladder outlet obstruction).
Subjects were randomized into four groups: placebo, 
5 mg finasteride, doxazosin (α1 blocker) titrated to 8 mg, and Therapeutics and Clinical Risk Management 2009:5 541
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a combination of both finasteride and doxazosin. Multiple 
outcome measures were assessed, including maximum flow 
rate, prostate volume, sexual function, and quality of life. 
While transrectal ultrasound and digital rectal exam were 
used to evaluate prostate volume, the Sexual Function Inven-
tory Questionnaire and the Short Form-36 Health Survey 
were used to evaluate sexual function and quality of life, 
respectively. Furthermore, prostate biopsies were obtained 
at baseline and at 5 years in 37% of volunteering study par-
ticipants (results described later).
Trial results revealed significant risk reductions in 
both monotherapy groups, with a 39% risk reduction 
by doxazosin (P  0.001) and 34% risk reduction for 
finasteride (P = 0.002) compared to placebo alone. The 
greatest risk reduction of clinical progression, however, 
was demonstrated with combination therapy (66% risk 
reduction) compared to doxazosin (P  0.001) or finasteride 
(P  0.001) alone. Additional markers of clinical progres-
sion such as acute urinary retention were decreased by 
finasteride (P  0.001) and combination therapy (P  0.001) 
but not doxazosin. Symptom scores were also improved 
in the finasteride (P = 0.001), doxazosin (P  0.001) and 
combination therapy (P  0.001) groups.
Subanalysis of the MTOPS trial further stratified patients 
by prostate size.35 This revealed that men with a prostate 
volume 25 cm3 achieved the greatest benefit from com-
bination therapy compared to finasteride or alpha-blocker 
monotherapy. Men with prostate volumes 25 to 40 cm3 
were also compared to those with volumes 40 cm3 and 
no difference in treatment effect with combination therapy 
was noted, indicating a lower threshold for prostate size with 
regard to treatment efficacy with combination α-blocker and 
finasteride therapy.
Given that long-term follow-up demonstrates a beneficial 
effect of finasteride, the next logical question is whether 
α1-blocker therapy may be withdrawn after a defined 
period of follow-up. Although no randomized clinical trials 
have been conducted for finasteride specifically, one trial 
has addressed this question with the dual type 1/type 2 
5α-reductase inhibitor, dutasteride.36 The Symptom Manage-
ment after Reducing Therapy (SMART-1) study examined 
this question by randomizing 327 BPH patients to 0.5 mg 
dutasteride and 0.4 mg tamsulosin for 36 weeks and 0.4 mg 
tamsulosin for 24 weeks followed by dutasteride and 
tamsulosin matched placebo for the remaining 12 weeks. 
Symptoms were assessed at weeks 24 and 30 with the IPSS. 
Results revealed that 77% of those who switched from 
combination therapy to dutasteride monotherapy did so 
without deterioration in their symptom score, indicating that 
α1-blockers may be safely removed from the combination 
after 24 weeks of therapy. Because the mechanism of dutas-
teride is believed to be similar to finasteride, the results of 
the study may be extrapolated to the latter. However, caution 
should be used in interpretation of the results as six weeks 
may be too short to provide conclusive evidence.
Tolerability of combination therapy
Safety and tolerability with combination therapy were 
evaluated in the MTOPS trial.7 While dizziness and postural 
hypotension were the most common side effects within the 
doxazosin group, erectile dysfunction, decreased libido and 
abnormal ejaculation were the most common encountered 
in the finasteride subset of patients, consistent with find-
ings from monotherapy studies. The individual adverse 
effects in the combination therapy group were similar to 
those for each drug alone with the exception of abnormal 
ejaculation, peripheral edema and dyspnea, which occurred 
more frequently in patients taking combination therapy. 
This adverse effect profile was confirmed with results of the 
PREDICT study.32
The discontinuation rate was surprisingly lower for the 
patients in the combination therapy (18%) compared to 
monotherapy with doxazosin (27%) or finasteride (24%) 
alone in the MTOPS trial. Of note, there were four patients 
who were diagnosed with breast cancer who received either 
finasteride alone or in combination with doxazosin. Unlike 
the MTOPS trial, the PREDICT study revealed almost identi-
cal discontinuation rates for the doxazosin (11.6%), finas-
teride (13.6%), combination (12.6%), and placebo (11.9%) 
groups.32 Regardless of the differences in these results, the 
common theme suggests tolerability of both monotherapy as 
well as combination therapy.
Role of finasteride for prostate 
cancer prevention and detection
Although this review focuses on the role of finasteride in 
treatment of benign prostatic hyperplasia, we would be 
remiss to exclude its role in prostate cancer prevention 
and detection, an important consideration when beginning 
patients on finasteride therapy. Because finasteride has been 
shown to reduce serum PSA, several studies have investi-
gated the extent and clinical impact of this phenomenon. 
Many reports have confirmed that finasteride reduces mean 
serum PSA levels by approximately 50%.37 Nevertheless, the 
effect on PSA is highly variable, and it is therefore considered 
useful to establish a baseline PSA level prior to initiation of Therapeutics and Clinical Risk Management 2009:5 542
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finasteride therapy. Biopsy for PSA elevation is warranted 
if the patient is on finasteride therapy, but is ultimately left 
to the discretion of the clinician.
The PLESS provided additional information regarding 
the impact of finasteride on detection of prostate cancer.38 
Three thousand forty men with PSA  10 ng/mL and no history 
of prostate cancer were randomized in this study to receive 
finasteride or placebo for up to 4 years. A pre-randomization 
biopsy was performed to confirm a negative status. 
Six hundred forty-four patients (21%) underwent biopsy. The 
decision to pursue a diagnosis of prostate cancer was left to 
the discretion of the investigator, providing a more realistic 
standard practice approach. The study revealed a diagnosis 
of prostate cancer in 4.7% of men on finasteride and 5.1% on 
placebo (P = 0.7), suggesting that finasteride does not mask 
the diagnosis of prostate cancer. Furthermore, elevated PSA 
prompted diagnosis in 35% of cases on finasteride and 34% on 
placebo using an upper PSA limit of 2.0 ng/mL for finasteride 
and 4.0 ng/mL for placebo, yielding similar sensitivity, higher 
specificity, and a higher likelihood ratio for finasteride when 
compared to placebo. The authors conclude that multiplication 
of the PSA by 2 and using normal ranges for untreated men 
seemed to preserve the usefulness of PSA in prostate cancer 
detection in men taking finasteride.
The largest study investigating prostate cancer prevention 
with finasteride was published by Thompson and cowork-
ers in 2003.39 Aptly named the Prostate Cancer Prevention 
Trial, the study randomized 18,882 men 55 years old with 
a normal DRE and PSA  3.0 ng/mL to treatment with 5 mg 
of finasteride or placebo for 7 years. Prostate biopsies were 
obtained if the annual PSA (adjusted for effect of finasteride) 
exceeded 4.0 ng/mL or if the DRE was felt to be abnormal. 
Primary end point was prevalence of prostate cancer. This 
outcome was detected in 803 (18.4%) in the finasteride group 
and 1147 (24.4%) in the placebo group, indicating a 24.8% 
risk reduction in prevalence over seven years (p  0.001). 
However, an alarming increase in high-grade 7 or above 
tumors were found in the finasteride group (37%) versus the 
placebo group (22%) (P  0.001).
Because of this anxiety-provoking finding of the Prostate 
Cancer Prevention Trial, subsequent analyses were performed 
which found that finasteride biases toward improved detection 
of prostate cancer as well as increased accuracy in prostate 
cancer grading at biopsy. Lucia and colleagues assessed 
whether the increased high-grade prostate cancer associated 
with finasteride in the PCPT was due to finasteride’s 
potential effects on tumor morphology or prostate size.40 
Prostate biopsies with Gleason scores 7–10 were examined. 
When possible, comparisons were made between these 
biopsies and sample from radical prostatectomies, examining 
for tumor grade and extent. Among patients undergoing 
prostatectomy, the finasteride-associated increase in high-
grade prostate cancer at biopsy was decreased at prosta-
tectomy (46% finasteride versus 39% placebo, P = 0.10), 
suggesting that finasteride’s effects on prostate volume was 
more likely the contributing factor for the increase in high-
grade cancers in this treatment group.
Another analysis accounted for these biases by estimating 
the effect of finasteride on the risk of overall and high-grade 
prostate cancer.41 Using estimated rates of high-grade prostate 
cancer based on analysis incorporating grading information 
from radical prostatectomies in 500 subjects, the resulting 
estimates for high-grade cancer rates were 8.2% versus 6.0% 
for placebo and finasteride, respectively demonstrating a 
statistically significant 27% risk reduction with finasteride 
(P = 0.02). Furthermore, a second analysis included 3-month 
longer collection of endpoints from the Prostate Cancer 
Prevention Trial (PCPT), revealing bias-adjusted prostate 
cancer rates of 21.1% (4.2% high-grade) in the placebo group 
versus 14.7% (4.8% high-grade) in the finasteride group, 
demonstrating a non-significant difference in high-grade 
cancers between the two groups (P = 0.12). These findings 
collectively propose caution in concluding that finasteride 
increases the risk of high grade prostate cancer.
Lucia and colleagues also addressed the concern that early 
detection by PSA and prevention by finasteride may involve 
biologically inconsequential tumors.42 Tumor pathology 
was stratified by level of PSA for men in the placebo group 
who underwent radical prostatectomy. Study findings 
demonstrated that low cutoff levels increase detection of 
insignificant disease but provides more likelihood for cure 
whereas higher cutoff levels demonstrate the opposite. Their 
recommendation was therefore to taylor cutoff values for 
PSA screening in those with finasteride, providing men with 
the information that finasteride may possibly decrease their 
risk of disease.
A Cochrane Database Systematic Review was published 
in April of 2008 and succinctly outlines conclusions from 
the PCPT.43 All randomized controlled trials published after 
1984 of at least 1 year duration were included in the review. 
Based on this review, the AUA recently released guidelines 
which address the role of finasteride in prostate cancer 
prevention.44 Asymptomatic men with PSA  3.0 ng/mL 
should be notified that finasteride may reduce the incidence of 
prostate cancer with an additional discussion of the elevated 
rate of high-grade cancer with potential explanations for Therapeutics and Clinical Risk Management 2009:5 543
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this potential risk. Furthermore, these patients should be 
informed that no information is known beyond seven years 
(as this was the duration of the largest trial [the PCPT]) 
and information regarding the reduction of prostate cancer 
mortality is unknown.
Cost
Because medical therapy for BPH may be necessary for 
many years, the cost effectiveness of this therapy compared 
to other modalities such as other pharmacologic agents as 
well as surgical options is an important consideration. While 
this has been informally discussed in several randomized 
controlled clinical trials, formal evaluation in the literature is 
limited. Johansen and colleagues investigated the cost effec-
tiveness of multiple management options for benign prostatic 
hyperplasia in men with moderate-to-severe lower urinary 
tract symptoms and enlarged prostates 30 cm3, including 
finasteride, dutasteride, tamsulosin and transurethral resec-
tion of prostate (TURP).45 Using a Markov model, the clinical 
progression of BPH in a cohort of 1000 men was estimated 
over 4- and 15.5-year periods in the Norwegian health 
system. Transitions between BPH symptoms, acute urinary 
retention, TURP, prostate cancer and death were estimated 
from the published literature, and sensitivity analyses were 
performed for direct and indirect costs for patients treated 
with dutasteride, finasteride, tamsulosin or TURP. Total costs 
for each of these treatment options at 15.5 years were  3,924, 
4,539,  4,946, and  6,164, respectively. The relative order 
of these costs was similar at 4 years. With these findings, 
dutasteride was found to be the most cost-effective, followed 
by finasteride and finally tamsulosin and TURP.
An abstract published by Lafuma and colleagues esti-
mated the cost-efficacy of finasteride, doxazosin, and their 
combination in the treatment of BPH in France.46 Using 
data compiled from the MTOPS study, cost records were 
extracted from the National Health Insurance website and 
costs were determined to be  7,404 for finasteride,  7,314 
for doxazosin and  8,206 for the combination. Cost-efficacy 
ratios were determined (additional drug costs per invasive 
therapy avoided) and found to be similar for finasteride and 
doxazosin and slightly higher for those with combination 
therapy. The investigators therefore concluded that the cost-
efficacy ratio of finasteride alone or in combination with 
doxazosin remained in the acceptable range.
Although these studies are based on international health 
care cost models, the MTOPS study does provide objec-
tive evidence that combination therapy may be the most 
cost effective approach.34 Results from the study indicate 
that the number needed to treat (NNT) to prevent a case of 
BPH progression was 13.7 and 15.0 for the doxazosin- and 
finasteride-monotherapy patients but only 8.4 for the com-
bination therapy group. The NNT was decreased further to 
4.7 and 4.9 when analyzing those patients with a baseline 
PSA  4.0 ng/mL and prostate size 40 cm3, respectively, 
suggesting that combination therapy becomes a more cost-
effective approach for men with enlarged prostates in any 
health care model.
Finally, cost-effectiveness for finasteride as a method of 
prostate cancer chemoprevention has recently been evaluated. 
Based upon data from the Prostate Cancer Prevention Trial, 
Svatek and associates used a Markov decision analysis model 
to determine lifetime prostate health-related costs (beginning 
at age 50) for men treated with finasteride versus placebo.47 
Results revealed a cost-effectiveness ratio of US$122,747 per 
quality-adjusted life-years saved (adjusted for US$112,062 if 
one assumes that finasteride does not increase the incidence 
of high-grade tumors). However, the cost-effectiveness ratio 
could be less than US$50,000 per quality of life years saved 
when applied to a high-risk population with cost of US$30 per 
month. Therefore, the conclusion was made that finasteride 
is unlikely to be cost-effective when considering impact of 
survival differences among treated and untreated men but 
potentially cost-effective in high risk populations when tak-
ing into consideration the impact of quality of life.
Conclusion
Numerous multi-center, randomized, double-blind, placebo-
controlled studies have supported the role of finasteride in 
the treatment of BPH. As monotherapy, it has been found to 
significantly reduce prostate volume by over 20% with addi-
tional overall treatment-related improvements in symptom 
score and peak flow rate. As an added benefit, finasteride has 
proven efficacious in the management of refractory hematu-
ria secondary to BPH and in preparation for TURP. Several 
studies have additionally investigated its role in combina-
tion therapy, and while short-term studies did not report a 
significant benefit, one long-term study revealed significant 
advantages with combination therapy with alpha-blockers 
to prevent BPH progression events such as acute urinary 
retention and need for BPH-related surgery. Treatment with 
finasteride has also been shown to reduce prostate cancer 
while maintaining the rate of detection, and patients should 
be informed of this fact while also indicating its possible (but 
unlikely) link to high grade prostate cancer and its unknown 
effect on prostate cancer mortality. Long-term safety and 
durability have been demonstrated in several studies with Therapeutics and Clinical Risk Management 2009:5 544
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the most common adverse clinical effect related to sexual 
dysfunction. Cost models have investigated its effective-
ness and found it a cost effective measure for treatment, 
especially for patients with moderate/severe symptoms and 
enlarged prostate 30 cm3 when compared to TURP and 
tamsulosin.
In conclusion, finasteride represents a cost-effective means 
of reducing BPH progression and its complications in men with 
enlarged prostates 30 cm3 while providing the additional 
benefits of decreased hematuria and prostate cancer rates.
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